ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
- Mechanism
- Curator reviewed
ETC-1001 is a synthetic, orally-active lipid regulating agent designed to elevate levels of high-density lipoprotein cholesterol (HDL-C), the "good" cholesterol. In pre-clinical studies, it shows the ability to elevate HDL-cholesterol levels, while also reducing levels of low-density lipoprotein cholesterol (LDL-C), the "bad" cholesterol, and triglycerides. It also inhibits the progression of atherosclerosis in pre- clinical models.
- Primary indication
- Investigated for use/treatment in hyperlipidemia.Curator reviewed
- Code names
- ETC-1001
Resolves to
Which companies are running trials of ETC-1001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account